EA-D p45-IgG as a potential biomarker for nasopharyngeal carcinoma diagnosis

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 12, 2013, Pages 7433-7438

  Chen, Hao ^a   Luo, Yao Ling ^a   Zhang, Lin ^a   Tian, Li Zhen ^b   Feng, Zhi Ting ^c   Liu, Wan Li ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b Department of Clinical Laboratory   (China)

^c GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Diagnosis; Early antigen; EBV; EBV nuclear antigen; NPC; Viral capsid antigen; Western blot

Indexed keywords

CAPSID PROTEIN; IMMUNOGLOBULIN G; TUMOR MARKER; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD; CANCER STAGING; CASE CONTROL STUDY; COMPARATIVE STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; NASOPHARYNX TUMOR; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; VIROLOGY;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84893356028     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.12.7433     Document Type: Article

References (31)

1. Ai P, Wang T, Zhang H, et al (2012). Determination of antibodies directed at EBV proteins expressed in both latent and lytic cycles in nasopharyngeal carcinoma. Oral Oncol, 49, 326-31.
2. Brooks L, Yao QY, Rickinson AB, Young LS (1992). Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: Coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol, 66, 2689-97.
3. Buisson M, Fleurent B, Mak M, et al (1999). Novel Immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation. J Clin Microbiol, 37, 2709-14.
4. Cao SM, Guo X, Li NW, et al (2006). Clinical analysis of 1, 142 hospitalized cantonese patients with nasopharyngeal carcinoma. Chin J Cancer, 25, 204-8.
5. Cao SM, Simons MJ, Qian CN (2011). The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer, 30, 114-9.
6. Chang KP, Hsu CL, Chang YL, et al (2008). Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: A possible alternative for primary screening of nasopharyngeal carcinoma. Oral Oncol, 44, 784-92.
7. Cochet C, Martel-Renoir D, Grunewald V, et al (1993). Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology, 197, 358-65.
8. De Vathaire F, Sancho Garnier H, De The H, et al (1988). Prognostic value of EBV markers in the clinical management of nasopharyngeal carcinoma (NPC).: A multicenter followup study. Int J Cancer, 42, 176-81.
9. Han BL, XuXY, Zhang CZ, et al (2012). Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev, 13, 2577-81.
10. Henle W, Henle G, Zajac BA, et al (1970). Differential reactivity of human serums with early antigens induced by Epstein-Barr virus. Science, 169, 188-90.
11. Henle W, Ho HC, Henle G, Kwan HC (1973). Antibodies to Epstein-Barr virus-related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors. J Natl Cancer Inst, 51, 361-9.
12. Ho HC, Ng MH, Kwan HC, Chau JC (1976). Epstein-Barr-virusspecific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br J Cancer, 34, 655-60.
13. Ji MF, Yu YL, Cheng WM, et al (2011). Detection of Stage I nasopharyngeal carcinoma by serologic screening and clinical examination. Chin J Cancer, 30, 120-3.
14. Lin JC, Jan JS, Hsu CY, et al (2003). Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival. J Clin Oncol, 21, 631-7.
15. Lin SY, Tsang NM, Kao SC, et al (2001). Presence of Epstein-Barr virus latent membrane protein 1 gene in the nasopharyngeal swabs from patients with nasopharyngeal carcinoma. Head Neck, 23, 194-200.
16. Lo YM, Chan LY, Lo KW, et al (1999). Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res, 59, 1188-91.
17. Luo YL, Ou GP, Chi PD, et al (2009). Combined determination of Epstein-Barr virus-related antibodies and antigens for diagnosis of nasopharyngeal carcinoma. Chin J Cancer, 28, 76-8.
18. Lynn TC, Tu SM, Kawamura A Jr (1985). Long-term follow-up of IgG and IgA antibodies against viral capsid antigens of Epstein-Barr virus in nasopharyngeal carcinoma. J Laryngol Otol, 99, 567-72.
19. Ng MH, Chan KH, Ng SP, Zong YS (2006). Epstein-Barr virus serology in early detection and screening of nasopharyngeal carcinoma. Chin J Cancer, 25, 250-6.
20. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM (2008). Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma. J Clin Virol, 42, 343-52.
21. Seong J, Park HC, Han KH, et al (2000). Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys, 47, 1331-5.
22. Sheen TS, Ko JY, Chang YL, et al (1998). Nasopharyngeal swab and PCR for the screening of nasopharyngeal carcinoma in the endemic area: A good supplement to the serologic screening. Head Neck, 20, 732-8.
23. Stevens SJ, Verkuijlen SA, Hariwiyanto B, et al (2005). Diagnostic value of measuring Epstein-Barr virus (EBV). DNA load and carcinoma-specific viral mRNA in relation to anti-EBV immunoglobulin a IgA and IgG antibody levels in blood of nasopharyngeal carcinoma patients from Indonesia. J Clin Microbiol, 43, 3066-73.
24. Su CK, Wang CC (2002). Prognostic value of Chinese race in nasopharyngeal cancer. Int J Radiat Oncol Biol Phys, 54, 752-8.
25. Tsang RK, Vlantis AC, Ho RW, et al (2004). Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review. Head Neck, 26, 598-602.
26. Wei KR, Xu Y, Zhang WJ, Liang ZH, Liu J (2011). Trend of changes on incidence and pathological proportions of nasopharyngeal carcinoma in Zhongshan city, Guangdong province, during 1970-2007. Zhonghua Liu Xing Bing Xue Za Zhi, 32, 1135-8.
27. Yau WL, Lung HL, Zabarovsky ER, et al (2006). Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. Int J Cancer, 119, 2821-6.
28. Yau TK, Lee AW, Wong DH, et al (2006). Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage? (a-b). nasopharyngeal carcinoma. Head Neck, 28, 880-7.
29. Yi Z, Yuxi L, Chunren L, et al (1980). Application of an immunoenzymatic method and an immunoautoradiographic method for a mass survey of nasopharyngeal carcinoma. Intervirology, 13, 162-8.
30. Zhang C, Zong Y, Huang B, et al (2002). Enhancing the efficiency of Epstein-Barr viral serologic test in the diagnosis of nasopharyngeal carcinoma. Zhonghua Zhong Liu Za Zhi, 24, 356-9.
31. Zong YS, Sham JS, Ng MH, et al (1992). Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer, 69, 3-7.